Trial Profile
A Phase I/II Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung, Bladder and Prostate Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Feb 2024
Price :
$35
*
At a glance
- Drugs EP-0057 (Primary) ; Olaparib (Primary)
- Indications Bladder cancer; Brain metastases; Carcinoma; Non-small cell lung cancer; Pelvic cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Nov 2021 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.
- 19 Dec 2020 Drug EP0057 has been added to the treatment regimen along with olaparib and CRLX101.
- 24 Jan 2020 Planned End Date changed from 31 Dec 2026 to 31 Dec 2027.